Production of anti- COVID drug Esperavir started in Russia

Promomed 18 February 2022

In Russia, the production of the first domestic drug for coronavirus based on the molnupiravir molecule has started. This active substance is recognized worldwide. Therapy with this drug allows doctors to cure even severe patients completely and in the shortest possible time.

Esperavir is called a new achievement in the treatment of coronavirus. This is the first anti-COVID drug registered in Russia based on the globally recognized molecule molnupiravir, which directly targets the virus. The new drug suppresses it even faster, which is fundamentally important in the combat against the pandemic.

«It cures COVID-19 in 5 days, this was made possible because it is a new molecule, new in its class, which has its unique targets in RdRp, a special enzyme that participates in the virus replication. This molecule does the job of destroying the virus much faster,» said Petr Bely, Chairman of the Board of Directors of Promomed Group.

The new drug inhibits viral replication by interrupting the copying of viral RNA. «This causes that new viral particles simply cannot be formed, the virus cannot replicate, it is eliminated from the body and, as a result, the patient recovers,» said Kira Zaslavskaya, Director for New Products at Promomed Group.

Patients also have a reduced risk of developing post-COVID complications. The new drug has already successfully passed all stages of clinical trials and is now being produced at pharmaceutical plant in Saransk.

«We are following the latest trends in international medical practice and we understand that the coronavirus is mutable, and new approaches and new drugs are needed for treatment. It is effective, it is safe,» commented Dmitry Zemskov, Executive Director of the Biokhimik plant of Promomed Group.

The number of requests for Esperavir is constantly increasing. The plant's capacity is sufficient to cover the demand of the Russian healthcare system.